Patrick T. McGann, MD, MS

Assistant Professor, UC Department of Pediatrics

Phone 513-803-4991

Email patrick.mcgann@cchmc.org

Dr. McGann was a leader in the development of a newborn screening and treatment program in the Republic of Angola. Toward this end, he worked and lived in Angola for much of two and a half years. This work helped to develop many relationships and is the foundation for much of his continued research and public health efforts in Angola. His research efforts during this time were supplemented by formal training in clinical research through the American Society of Hematology's Clinical Research Training Institute and through the master's program in clinical research at Baylor College of Medicine.

He is also actively involved in global hematology and global child health through such organizations as the Global Sickle Cell Disease Network, the Central African Sickle Cell Network (REDAC), the American Society of Hematology, and the AAP's Section on International Child Health (SOICH). 

Upon arrival to Cincinnati Children's, Dr. McGann was the recipient of the Procter Scholar Award, which will help to support his international research efforts.

MD: Tufts University School of Medicine, Boston, MA 2006.

Residency: Pediatrics, Massachusetts General Hospital, Boston, MA 2009.

Fellowship: Pediatric Hematology-Oncology, St. Jude Children's Research Hospital, 2009-2011; Baylor College of Medicine, 2011-2012.

MS: Clinical Research, Baylor College of Medicine, 2013.

Board Certification: Pediatrics, 2009; Pediatric Hematology-Oncology, 2013.

McGann PT, Bernardino L. Anemia falciforme: um grande problema de saúde pública em Angola. Jornal Angolano de Medicina. 2013; 1(3).

McGann PT, Ferris MG, Ramamurthy, U, Santos, B, de Oliveira V, Bernardino L, Ware RE.  A pilot newborn screening and treatment for sickle cell anemia in the Republic of Angola. Am J Hematol. 2013; 88(12):984-989.

Despotovic JM, McGann PT, Smeltzer MP, Aygun B, Ware RE. RHD zygosity predicts degree of platelet response to anti-D immune globulin treatment in children with immune thrombocytopenia. Pediatr Blood Cancer. 2013; 60(9):E106-108.

McGann PT, Flanagan JM, Howard TA, Dertinger SD, He J, Kulharya A, Thompson BW, Ware RE. Genotoxicity associated with hydroxyurea exposure in infants with sickle cell anemia: Results from the BABY-HUG phase III clinical trial. Pediatr Blood Cancer. 2012; 59(2) 254-257.

McGann PT, Despotovic JM, Howard TA, Ware RE. A novel laboratory technique demonstrating the influences of RHD zygosity and the RhCcEe phenotype on erythrocyte D antigen expression. Am J Hematol. 2012; 87(3): 266-271.

McGann PT, Ware RE. Hydroxyurea for sickle cell anemia: what have we learned and what questions still remain?Curr Opin Hematol. 2011 May;18(3):158-65.

McGann PT, Howard TA, Flanagan JM, Lahti JM, Ware RE. Chromosome damage and repair in children with sickle cell anaemia and long-term hydroxycarbamide exposure. Br J Haematol. 2011; 154(1):134-40.

McGann PT, McDade J, Mortier NA, Combs MR, Ware RE. IgA-mediated autoimmune hemolytic anemia in an infant. Pediatr Blood Cancer. 2011; 56(5):837-9.

McDade J, McGann PT. 50 Years Ago in The Journal of Pediatrics: Autohemolytic Anemia in Young Infants. J Pediatr. 2011; 159(1):69.

McGann PT, Ware RE. 50 years ago in the journal of pediatrics overwhelming infection in children following splenectomy. J Pediatr. 2010; 157(2):202.

A Phase I/II Study of Hydroxyurea for Children with Sickle Cell Anemia in Angola. Principal Investigator. Procter Scholar Award, Cincinnanti Children's Hospital Medical Center TAPS Program. Jan 2014-Dec 2016.

Sickle Cell Education and Screening for Angolan Adolescents. Co-Director/Mentor. AAP International Community Access to Child Health (ICATCH), Jan 2014-Dec 2016.